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Abstract 
Background: Characterization of genes linked to bone metastasis is critical for identification of novel prognostic 
or predictive biomarkers and potential therapeutic targets in metastatic castrate‑resistant prostate cancer (mCRPC). 
Although bone marrow core biopsies (BMBx) can be obtained for gene profiling, the procedure itself is invasive and 
uncommon practice in mCRPC patients. Conversely, circulating tumor cells (CTCs), which are likely to stem from bone 
metastases, can be isolated from blood. The goals of this exploratory study were to establish a sensitive methodology 
to analyze gene expression in BMBx and CTCs, and to determine whether the presence or absence of detectable gene 
expression is concordant in matching samples from mCRPC patients.
Methods: The CellSearch® platform was used to enrich and enumerate CTCs. Low numbers of PC3 prostate cancer 
(PCa) cells were spiked into normal blood to assess cell recovery rate. RNA extracted from recovered PC3 cells was 
amplified using an Eberwine‑based procedure to obtain antisense mRNA (aRNA), and assess the linearity of the RNA 
amplification method. In this pilot study, RNAs extracted from CTCs and PCa cells microdissected from formalin‑fixed 
paraffin‑embedded BMBx, were amplified to obtain aRNA and assess the expression of eight genes functionally rel‑
evant to PCa bone metastasis using RT‑PCR.
Results: RNAs were successfully extracted from as few as 1–5 PCa cells in blood samples. The relative expression 
levels of reference genes were maintained after RNA amplification. The integrity of the amplified RNA was also 
demonstrated by RT‑PCR analysis using primer sets that target the 5′‑end, middle, and 3′‑end of reference mRNA. We 
found that in 21 out of 28 comparisons, the presence or absence of detectable gene expression in CTCs and PCa cells 
microdissected from single bone lesions of the same patients was concordant.
Conclusions: This exploratory analysis suggests that aRNA amplification through in vitro transcription may be useful 
as a method to detect gene expression in small numbers of CTCs and tumor cells microdissected from bone meta‑
static lesions. In some cases, gene expression in CTCs and BMBxs was not concordant, raising questions about using 
CTC gene expression to make clinical decisions.
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Background
More than 80 % of patients with metastatic castrate-resist-
ant prostate cancer (mCRPC) present skeletal metastases, 
which invariably lead to an incurable disease for which we 
only have treatments that become palliative in nature [1, 
2]. Thus, the identification of gene signatures pertaining 
to prostate cancer (PCa) bone metastasis is fundamental 
to the development of novel therapeutic targets and/or 
the identification of prognostic or predictive biomarkers.
The vast majority of gene profile analyses using biop-
sies from PCa patients have been performed in primary 
tumors or metastatic lesions other than bone [3–5], which 
might not provide clues about gene transcriptional changes 
occurring in skeletal metastasis. Although gene analysis of 
bone marrow core biopsies (BMBxs) would be of impor-
tance to identify the genetic make-up of PCa cells that colo-
nize and interact with the bone microenvironment, BMBxs 
are not routinely performed in mCRPC patients due to 
the time-consuming and invasive nature of the procedure. 
Furthermore, in most cases, the combination of imag-
ing studies and clinical information has proven to provide 
diagnostic accuracy for the assessment of suspected bone 
metastases [6]. In contrast, circulating tumor cells (CTCs) 
can be obtained repeatedly and non-invasively through 
routine blood draws, and isolated through different tech-
niques utilizing cell-surface antigens, or other physical, 
and/or biological properties of cancer cells [7–9].
CTCs are rare cancer cells transported through the 
peripheral circulation. In localized, non-metastatic can-
cers, CTCs are thought to emanate from primary tumors. 
CTCs may also be released from metastatic lesions and 
found in peripheral blood of patients with advanced can-
cer, thus providing an opportunity for “liquid biopsy” that 
may offer information on the evolution of the disease 
during treatment [9, 10]. The assessment of CTC num-
bers using the CellSearch® platform has been validated 
as a tool of clinical utility to monitor treatment response 
and predict survival in mCRPC patients [11].
Previous studies by others have demonstrated clearly the 
capacity of gene expression analyses of RNA obtained in 
large amounts from bone metastases derived from rapid 
autopsies of PCa patients [12, 13]. Here, we wished to deter-
mine the feasibility of gene expression analysis of both CTCs 
and BMBxs in living mCRPC patients with bone scan evi-
dence of skeletal metastasis. Since CTCs in mCRPC patients 
are likely to derive from bone metastatic deposits, we also 
aimed to explore similarities/differences in gene expression 
in both CTCs and BMBxs obtained from the same patients.
Methods
Cell culture
PC3 and LNCaP PCa cells were obtained from ATCC 
(Manassas, VA) and provided by Dr. Leland Chung 
(Cedars-Sinai Medical Center, Los Angeles, CA), respec-
tively. Both cell lines were grown in RPMI-1640 with 10 % 
heat-inactivated fetal bovine serum (FBS). Authentication 
of the human cell lines used here was verified through 
short tandem repeat profiling by the Research Technol-
ogy Support Facility of Michigan State University.
Cell spike‑in experiments
For validation studies, 80  % confluent PC3 and LNCaP 
monolayers were trypsinized, and diluted in complete 
culture medium to adjust their cell density to 50  cells/
mL. Cell suspensions (100 μL) were plated into the wells 
of 96-well cell culture plates. Twenty-four hours later, 
cells in all wells were counted under the microscope, and 
those with exactly five cells were trypsinized and added 
to 7.5 mL of blood from healthy volunteer donors drawn 
into CellSave® preservative tubes (Janssen Diagnostics, 
LLC). CellSave® tubes containing blood spiked with cul-
tured PCa cells, as well as matched non-spiked blood 
samples serving as negative controls, were processed in 
triplicate using the semiautomated CellSearch® Circu-
lating Epithelial Cell Kit (Janssen) in the CellTracks® 
Autoprep® system (Janssen) for cell enumeration at the 
Biobanking and Correlative Sciences Core at Karma-
nos Cancer Institute. Briefly, epithelial cells present in 
peripheral blood were magnetically captured with a 
ferrofluid-coupled antibody targeting the epithelial cell 
adhesion molecule (EpCAM), then immunostained with 
allophycocyanin (APC)-labeled antibodies to the leuko-
cyte marker CD45, phycoerythrin (PE)-labeled antibod-
ies to epithelial markers cytokeratins (CKs) 8, 18, and 
19, and stained with the nuclear stain 4,2-diamidino-
2-phenylindole-dihydrochloride (DAPI). The sample was 
transferred automatically to a cartridge in a MagNest, 
and finally scanned with the semi-automated fluores-
cence optical system Cell-Tracks Analyzer II® (Janssen). 
Objects preselected and displayed by the system in a 
gallery were defined as CTCs and counted by a trained 
operator if they were round to oval in shape, 4 µm in size 
or larger, positive for the epithelial marker (CK-PE) and 
nuclear stain (DAPI) with at least 50 % overlap between 
the CK-PE-positive cytoplasm and the nucleus, and neg-
ative for the leukocyte marker (CD45-APC). In addition, 
5 PC3 or LNCaP cells were spiked into 7.5 mL of blood 
from healthy volunteer donors drawn into fixative-free 
K3EDTA tubes (BD Vacutainer®, Becton–Dickinson) 
(three experiments performed by three different investi-
gators), to validate the sensitivity of the RNA amplifica-
tion method used by us (see description below). To this 
end, the spiked blood was immediately processed using 
the CellSearch® Profile Kit (Janssen) and the CellTracks® 
Autoprep® system, and then the tube employed con-
taining a final volume of 900  µL CTC enriched sample 
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was placed in a DynaMag™-15 magnet (Invitrogen) for 
10 min. After carefully aspirating the liquid without dis-
turbing the ferrofluid bead pellet concentrated on the 
tube wall, 1 mL of TRIzol® (Invitrogen) was added, and 
the tube vortexed to lyse cells and inactivate nucleases. 
The lysate was transferred to a 1.5 mL RNase-free Eppen-
dorf tube, and stored at −80 °C until RNA isolation and 
antisense RNA (aRNA) amplification was performed.
Patient enrollment and eligibility
Written informed consent was obtained from 24 mCRPC 
patients enrolled to participate in the human protocol # 
2011-060 (Principal Investigator: Dr. Michael L. Cher), 
and approved by Karmanos Cancer Institute and Wayne 
State University Institutional Review Board. Study inclu-
sion criteria were: (a) prior diagnosis of mCRPC charac-
terized by rising PSA level or clinical disease progression 
despite a castrate level of serum testosterone; (b) clini-
cal decision to start a new anti-cancer systemic therapy, 
and no treatment with any investigational drug within 
2  weeks prior to blood draw/tissue biopsy proposed 
herein; (c) metastatic deposit visible on an imaging study 
obtained within 8  weeks prior to initiation of new sys-
temic therapy; (d) radiological evidence of accessibility 
to a metastatic deposit in bone by computed tomography 
(CT); (e) performance status of 0–2 by ECOG/Zubrod 
criteria; (f ) Absolute neutrophil count  ≥1500  mm3, 
hemoglobin ≥9.0 g/dL, platelets ≥100,000/mm3; (g) Pro-
thrombin Time and Partial Thromboplastin Time should 
be < institutional upper limit of normal; (h) presence of 
one or more CTCs per 7.5 mL, assessed using the Veri-
dex CellSearch® Profile Kit assay, as explained above. The 
characteristics of the patients enrolled in this study are 
described in Table 1.
Blood sample processing
Blood from each patient was initially collected in Cell-
Save® preservative tubes and processed for CTC enumer-
ation as described above. Patients who were positive for 
CTCs were subjected to a new blood draw into K3EDTA 
anticoagulant tubes used in the CellSearch® Profile Kit, 
for CTC enrichment and RNA extraction as described 
above. The TRIzol® lysate obtained was transferred to a 
1.5 mL RNase-free Eppendorf tube, and stored at -80 °C 
until needed.
Procurement and processing of tumor tissue from bone 
metastases
On the same day blood was drawn for CTC enrichment 
and RNA extraction, patients then underwent CT-guided 
BMBx using a battery-powered drill and biopsy nee-
dle set. Four to six BMBxs were obtained from the iliac 
bone of each patient. One of the cores was placed in an 
RNase-free Eppendorf tube and flash frozen and trans-
ported in liquid nitrogen for storage at −80  °C until 
processing. The remaining BMBxs were fixed for 24 h in 
4 % paraformaldehyde in diethylpyrocarbonate (DEPC)-
treated PBS, and decalcified in 10 % EDTA in autoclaved 
DEPC-treated water, pH 7.0, with agitation at room tem-
perature for 3 days. After decalcification, each BMBx was 
progressively dehydrated with increasing concentrations 
of ethanol, and immediately paraffin-embedded using 
Precision Cut Paraffin (Thermo Scientific). All aqueous 
solutions were prepared using DEPC-treated water.
Laser capture microdissection
Two adjacent 5-µm sections were obtained from the for-
malin-fixed paraffin-embedded (FFPE) BMBxs, using at 
all times RNase-free technique. Immunohistochemistry 
(IHC) for cytokeratin was performed on one of the slides 
for identification of PCa cells, as previously described 
[14, 15], as PCa cells are the only cytokeratin-positive 
cells expected to be found within the BMBx. The adjacent 
tissue section was mounted onto an RNase-free polyeth-
ylene naphthalate (PEN) membrane glass slide (Arctu-
rus), which was previously sprayed with RNase AWAY™ 
Table 1 Demographic and clinical parameters of evaluable 
mCRPC patients
Data between parentheses are percentage
AP alkaline phosphatase; CTC circulating tumor cell; PSA prostate-specific 
antigen
a  At time of enrollment. Not available for three patients due to unavailability of 
pathological results









Gleason scorea 5 (33)
8–10 8 (53.5)
Not available 2 (13.5)
PSA (ng/mL) Median 70.8
Range 1.9–1299
AP (U/L) Median 437.5
Range 65–1224
Metastases Bone only 11 (73)
Bone and soft tissue 2 (13.5)
Bone and unknownb 2 (13.5)
CTC/7.5 mL Median 20
Range 1–834
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(Thermo Scientific), washed twice with DEPC-treated, 
nuclease-free water (Fisher Scientific), and then exposed 
to UV for 30  min under a laminar flow hood to render 
the PEN membrane more hydrophilic and improve 
adherence of the specimen. After air drying for about 
2 h under a laminar flow hood, the section mounted on 
the slide was deparaffinized, hydrated with decreasing 
graded alcohols made with DEPC-treated water, and 
rapidly stained with Harris hematoxylin and alcoholic 
Eosin Y solution (H&E), washed twice with 100 % etha-
nol and xylene, then held in xylene until initiation of the 
laser capture microdissection (LCM) session. The H&E-
stained slide was air dried and loaded onto the Arctu-
rusXT™ LCM System. Metastatic lesions identified in 
the FFPE sample were excised using both the infrared 
(IR) and ultraviolet (UV) microdissection lasers, and col-
lected on individual CapSure® Macro LCM Caps (Arctu-
rus). When needed, the adjacent section immunostained 
for cytokeratin was used for guidance during the LCM 
session to identify epithelial (PCa) cells within the bone 
marrow. Tumor material was deemed to be inadequate 
for LCM and RNA collection if the area identified as 
tumor was smaller than 9000 µm2, with 150 PCa cells on 
average. To collect total RNA from the microdissected 
tissue, the CapSure® Macro LCM Cap containing the 
captured material was immediately placed into a 0.5 mL 
RNase-free microcentrifuge tube filled with 50  µL of 
TRIzol® reagent, vortexed for 5 min to lyse the cells, and 
the lysate obtained stored at −80 °C until needed.
RNA isolation and amplification of small amounts of RNA
Cultured PCa cells and CTCs were lysed with TRIzol® 
reagent, as described above. Flash frozen BMBxs were 
placed in pre-chilled microtubes containing 2.8  mm 
ceramic beads and TRIzol® reagent using a Precellys®24 
homogenizer (Peqlab LLC), 1 cycle × 30 s at 6000 rpm at 
4  °C, similarly as described by others [16]. High-quality 
total RNA (DNA-free) was purified from cultured cells, 
CTCs, LCM, and frozen BMBxs lysed with TRIzol® using 
Direct-zol™ RNA MiniPrep (Zymo Research), as per 
manufacturer’s instructions. For gene analysis of CTCs 
enriched from patients’ blood, spiked-in cultured cells, or 
tumor cells metastatic to bone recovered by LCM, RNAs 
were amplified using an antisense mRNA (aRNA) ampli-
fication system based on the Eberwine’s procedure [17], 
using the MessageAmp™ II aRNA Amplification Kit (Inv-
itrogen). The protocol was performed as recommended 
by the manufacturer, except for the replacement of Array-
Script™ RT by Superscript® VILO™ Master Mix (Invitro-
gen) and the replacement of 10 × First Strand buffer from 
MessageAmp™ II aRNA Amplification Kit (Invitrogen) 
by 5 ×   First Strand buffer from Superscript® II Reverse 
Transcriptase (Invitrogen). This was done to increase the 
reverse transcription (RT) of total RNA into a first strand 
of complimentary DNA (cDNA). SuperScript® VILO™ 
Master Mix contains a recombinant ribonuclease inhibi-
tor and SuperScript® III RT, which is among the best 
performing reverse transcriptases in terms of reproduc-
ibility and sensitivity for low copy RNA levels [18]. After 
RNase treatment, a second strand cDNA is generated by 
DNA polymerase. The resulting double-stranded cDNA 
was then used as a template for T7-RNA polymerase for 
in  vitro transcription (IVT) into aRNA (also known as 
complimentary RNA, cRNA) and amplification. The pro-
cedure was repeated in a second round of amplification 
when additional aRNA yield was needed. After IVT, dou-
ble-stranded cDNAs were removed by treatment with 
DNase I, and the amplified RNA was purified.
Concentrations of total RNA and amplified aRNA 
obtained from cells spiked in blood, as well as from 
amplified aRNA obtained from CTCs and flash frozen or 
FFPE BMBxs, were quantified by absorbance measure-
ments using an Epoch™ Microplate Spectrophotometer 
for micro-volume analysis (BioTek). Purity of total RNA 
and amplified aRNA was assessed through the ratio of 
the absorbance of the samples at 260 and 280 nm (A260/
A280).
Assessment of amplified aRNA integrity
Integrity of mRNA is usually assessed by the ratio of 
the 28S:18S rRNA species shown in denaturing agarose 
gel electrophoresis, based on the assumption that the 
quality of rRNA (more than 80 % of total RNA) reflects 
that of underlying mRNA. However, this approach can-
not be used to assess the integrity of amplified aRNA, 
which does not contain rRNA and derives from minute 
amounts of total RNA. Therefore, we assessed the integ-
rity of aRNA with RT-PCR (see below) using two sets of 
primers to probe different positions (5′ end, middle, and 
3′ end regions) of EpCAM and GAPDH transcripts, by 
verifying the presence of each respective amplicon on 
agarose gels (Fig. 2a), following a strategy similar to that 
described by Nolan [19].
Gene expression analysis
Total RNA or amplified aRNA was reverse transcribed 
into cDNA using iScript™ cDNA synthesis kit (Bio-Rad) 
according to manufacturer’s protocol. For RT-PCR, 
resultant cDNAs were used as a template in a PCR reac-
tion using DreamTaq DNA polymerase (Life Technolo-
gies). Forward and reverse primers used are listed in 
Table  2. The following amplification conditions were 
used: an initial denaturation at 95 °C for 3 min, followed 
by 35–40 cycles (except for GAPDH, 25 cycles) of 95 °C 
for 30 s, 52–55 °C for 30 s and 72 °C for 1 min, followed 
by a final extension 72 °C for 5 min. PCR products were 
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resolved on a 2 % agarose gel and visualized by ethidium 
bromide staining. DNA bands were visualized using a 
ChemiDoc XRS gel documentation system (Bio-Rad).
For reverse transcriptase quantitative real-time 
quantitative PCR (RT-qPCR), the Mastercycler Real-
Plex2 (Eppendorf ) real-time PCR system and GoTaq 
qPCR Master Mix (Promega) were used. Thermal cycle 
parameters were as follows: initial activation at 95  °C 
for 2  min,  40 cycles of denaturation at 95  °C for 15  s, 
annealing 55 °C for 15 s, and extension at 72 °C for 30 s. 
The mean cycle threshold (Ct) for each gene was nor-
malized to levels of the housekeeping gene GAPDH in 
the same sample. Relative fold changes in expression 
for each gene were calculated by the delta–delta-CT 
method [20].
As a proof of concept, we selected eight genes for 
analysis with RT-PCR in CTCs and LCM BMBxs based 
on their relevance to PCa bone metastasis: (a) EpCAM, 
which codes for a transmembrane epithelial glycoprotein 
[21] overexpressed in adenocarcinomas [22] and used 
in the CellSearch® system to enrich CTCs via immuno-
magnetic separation; (b) PSA (prostate-specific anti-
gen), a well know biomarker for PCa screening found 
to be positive in mCRPC patients [23]; (c) BMP-7 (bone 
morphogenetic protein-7), a member of the transform-
ing growth factor-beta (TGF-β) family that is usually 
expressed in osteoblastic bone metastases of PCa [24], 
and increased in CRPC patients [25]; (d) MMP-14 (a.k.a. 
MT1-MMP), a membrane-tethered matrix metallopro-
teinase that we found to be expressed by PCa cells in 
skeletal metastases, and contribute to bone remodeling 
and intraosseous tumor growth [26]; (e) TMPRSS2-ERG 
gene rearrangement due to chromosomal translocations 
that fuse the androgen-regulated TMPRSS2 promoter 
with the ETS family transcription factor ERG, which is 
expressed in about half of advanced PCas [27–29] and 
has been associated with an increased risk death in PCa 
patients [30–32]; (f ) IL-6 (interleukin-6), which is highly 
expressed by PCa cells with aggressive phenotype [33], 
and has been associated with resistance to chemotherapy 
in CRPC [34] and bone remodeling in PCa bone metasta-
ses [35, 36]; (g) Vimentin, an intermediate filament pro-
tein expressed in mesenchymal cells frequently used as 
a marker of epithelial to mesenchymal transition (EMT) 
[37]; and (h) GAPDH, a housekeeping gene used as a 
control.
Table 2 Primer pairs used for RT-PCR and RT-qPCR studies
FWD forward primer; REV reverse primer; bp base pairs; t-ERG, TMPRSS2 exon 1 and ERG exon 4 (TMPRSS2-ERG) fusion product
Gene ID Accession number Oligonucleotides (5′ →3′) Amplicon size (bp)
BMP7 NM 001719 FWD: TACGCCGCCTACTACTGTGA
REV: CCGGACCACCATGTTTCTGTA
219
CD45 NM 002838 FWD: AGCACCTACCCTGCTCAGAA
REV: TTCAGCCTGTTCCTTTGCTT
159
5′‑EpCAM NM 002354 FWD: CAGGTCCTCGCGTTCGGG
REV: CAGTCAGGATCATAAAGCCCATCA
284
Middle EpCAM NM 002354 FWD: AATGGACCTGACAGTAAATGG
REV: ATCTCAGCCTTCTCATAC TT
216
3′‑EpCAM NM 002354 FWD: TGGGGAACAACTGGATCTGG
REV: GTTCCCTATGCATCTCACCCA
227
5′‑GAPDH NM 002046 FWD: GGAAGGTGAAGGTCGGAGTC
REV: CTCGCTCCTGGAAGATGGTG
237
Middle GAPDH NM 002046 FWD: GAGAAGGCTGGGGCTCATTT
REV: AGTGATGGCATGGACTGTGG
231
3′‑GAPDH NM 002046 FWD: AAGGTCATCCCTGAGCTGAA
REV: TGACAAAGTGGTCGTTGAGG
271
IL6 NM 000600 FWD: AATGAGGAGACTTGCCTGGTG
REV: GCTGCGCAGAATGAGATGAG
273
MMP14 NM 004995 FWD: AGTCTCCCAGAGGGTCATTCA
REV: GGTCCCATGGCGTCTGAAG
320
SNAI 2 NM 003068 FWD: CTTTTTCTTGCCCTCACTGC
REV: ACAGCAGCCAGATTCCTCAT
161
t‑ERG FJ423744 FWD: TMPRSS2_E1‑TAGGCGCGAGCTAAGCAG
REV: EGR_E4‑GTCCATAGTCGCTGGAGGAG
184
Vimentin NM 003380 FWD: GAGAACTTTGCCGTTGAAGC
REV: TCCAGCAGCTTCCTGTAGGT
170
ZEB 1 NM 030751 FWD: TGCACTGAGTGTGGAAAAGC
REV: TGGTGATGCTGAAAGAGACG
237
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Statistical analysis
Data obtained using RT-qPCR are presented as mean 
values ±  SD and analyzed using the ANOVA test, with 
p < 0.05 considered as statistically significant.
Results
Validation of linear amplification of RNA for gene analysis 
in small number of PCa cells
To mimic the CTC number threshold currently used to 
predict overall survival (OS) in men with mCRPC [11, 21, 
38–40] and establish the method for RNA amplification 
from limited quantities of total RNA for gene expression, 
we spiked blood from healthy male volunteers with five 
PC3 or 5 LNCaP cells. Using the CellSearch® Circulating 
Epithelial Cell Kit in the CellTracks® Autoprep® system, 
we found that the recovery rate of PC3 and LNCaP cells 
spiked into normal blood was 76.7 ± 6.2 % (n = 6) and 
80.2 ± 3.0 % (n = 6) at the five and 50 cell level, respec-
tively, confirming high efficiency of PCa cell recovery 
from blood. No epithelial cells were found in non-spiked 
matched blood used as negative controls. After we con-
firmed the cell recovery rate using the Circulating Epi-
thelial Cell enrichment system, we then spiked five PC3 
or LNCaP cells in new blood of healthy men drawn in 
K3EDTA tubes and processed using the CellSearch® Pro-
file Kit, used for RNA analysis. Minute amounts of total 
RNA extracted from the PC3 and LNCaP cells recovered 
through that CellSearch® Profile Kit and the CellTracks® 
Autoprep® system were subjected to one and two round 
amplification using the MessageAmp™ II aRNA Ampli-
fication Kit. As shown in Table 3, this methodology was 
efficient enough to generate sufficient quantities of aRNA 
of good quality (A260/A280 ratio of 1.8–2.0) from a few 
PCa cells for gene expression analyses, such as RT-PCR, 
RT-qPCR, and cDNA microarrays if desired. To establish 
the nature of linear amplification, we compared relative 
expression levels in a set of genes with high, medium, 
or low expression levels, in unamplified RNA extracted 
from 2 × 105 PC3 cells (~6–9 µg of total RNA, equiva-
lent to  ~180–270  pg of mRNA) and one- or two-round 
amplified aRNA derived from five PC3 cells (Table  3). 
The relative abundance of transcripts for the different 
genes assessed by RT-qPCR was maintained, confirming 
the linear amplification of RNA (Fig. 1).
Gene expression analysis in CTCs and BMBx from mCRPC 
patients with bone metastasis
To check the purity and quality of the aRNA amplified 
from RNA extracted from CTCs and PCa cells micro-
dissected from BMBxs, we designed primers to target 
different regions of EpCAM and GAPDH transcripts, 
epithelium-specific and housekeeping genes, respectively 
(Fig. 2a). The primers targeting the 5′ end and the mid-
dle regions of the transcripts produced the expected size 
of the resultant PCR products as effectively as those tar-
geting the 3′ end (Fig. 2b), indicating that the integrity of 
the aRNA amplified from both CTCs and microdissected 
FFPE PCa bone metastases was good. Having confirmed 
that the quality of the amplified aRNA was adequate, we 
analyzed all the CTC and BMBx samples included in the 
study using RT-PCR.
Of 24 patients with bone scan/CT scan evidence of 
one or more skeletal metastases enrolled in the study, 
nine had no CTCs and therefore did not undergo 
bone biopsy. Table  1 summarizes the demographic, 
clinical, and tumor characteristics of the 15 patients 
that had one or more EpCAM-positive CTCs in their 
blood. One patient was eliminated from the study due 
to undetectable aRNA in CTCs even after two-rounds 
of amplification. In addition, another patient was 
excluded because his BMBx showed sarcomatoid tumor 
cells. Of the 13 patients remaining, a second blood 
sample was obtained and subjected to CTC enrichment 
using the CellSearch® Profile kit for RNA extraction, 
and subsequent aRNA amplification. RT-PCR analy-
sis of aRNA amplified from CTCs revealed that the 
gene expression varied from one patient to another. As 
expected, EpCAM, which codes for the protein used 
for CTC enrichment, was expressed in all cases. PSA 
and IL-6 were also expressed by CTCs from all patients 
(Fig. 3a). Unexpectedly, the transcript for Vimentin was 
expressed in many of patients’ CTCs (Fig.  3a). Impor-
tantly, aRNA amplification from as little as one CTC 
(e.g., patient 04  M–S) was sufficient to perform gene 
analysis, consistent with our results with amplified 
aRNA obtained from five cultured PCa cells.
Of 13 patients with detectable CTCs, 7 (54  %) had 
cytokeratin-positive cells on immunohistochemical 
Table 3 Yield of aRNA after one and two rounds of amplifi-
cation of RNA obtained from five cultured prostate cancer 
cells
a  Calculated based on measurement of total RNA from 106 cells
b  Based on the assumption that 3 % of total RNA is mRNA
Cell line Median (range) 
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analysis of their BMBx. This yield is consistent with that 
reported in the literature [41, 42]. However, only four had 
a large enough area occupied by cancer cells for LCM 
and RNA collection. In those cases, we compared aRNA 
amplified from RNA extracted from ground flash frozen 
BMBx with that obtained from LCM FFPE sections of 
matching BMBx of the same patient. In the latter, areas 
exclusively containing PCa cells, as identified by H&E 
and confirmed by IHC for pan-CK, were UV laser micro-
dissected from the bone specimens mounted on mem-
brane glass slides, and captured with the help of a gentle 
IR laser, using the ArcturusXT™ LCM System (Fig.  3b). 
We observed that, although RNA yield was better in 
ground frozen bone core biopsies, the expression level 
of most of the genes specific to PCa was considerably 
diminished compared to amplified aRNA derived from 
PCa cells microdissected from FFPE BMBxs after equal 
number of PCR cycles and normalization to GAPDH 
(not shown). Conversely, genes commonly expressed by 
bone cells, such as RANK (receptor activator of nuclear 
factor κ-B), were highly expressed in aRNA derived from 
ground frozen BMBx, but minimally or not expressed 




































~ 2x105 PC3 cells
Fig. 1 Comparison of gene transcript levels in total RNA and ampli‑
fied aRNA. Transcriptional profiles assessed by RT‑qPCR for genes with 
high (EpCAM), intermediate (SNAI2, ZEB1), and low (BRCA2) expres‑
sion levels in total RNA from high number of cultured PC3 cells, and 
amplified aRNA from five PC3 cells spiked in blood after CellSearch® 
Profile kit processing. Relative expression of genes was normalized 
to that of GAPDH, calculated by the delta–delta‑CT method. No sig‑
nificant statistical differences in relative expression for each particular 
transcript were observed among non‑amplified mRNA, one‑round 
amplified aRNA, and two‑round amplified aRNA, as per analysis of 
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Fig. 2 Quality of aRNA amplified from CTCs and LCM bone metastases from mCRPC patients. a Primers designed to amplify 5′‑end, middle (M), and 
3′‑end fragments of EpCAM and GAPDH transcripts. b RT‑PCR products obtained for amplified aRNA derived from CTCs and laser microdissected 
tumor cells metastatic to bone of three mCRPC patients, using the two sets of primers targeting different regions of EpCAM and GAPDH
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FFPE BMBx (not shown). These results demonstrate that 
analysis of frozen bone samples is limited by contamina-
tion with normal bone cells.
Using at all times RNase-free instruments and tech-
nique, and aqueous reagents prepared in nuclease-free 
water, we were able to amplify good quality aRNA from 
the total RNA collected from the FFPE BMBxs (Fig. 2b). 
Since the aRNA yield obtained was good, we analyzed 
in BMBxs the same genes studied in CTCs (Fig.  3c). In 
order to explore whether or not there was concordance 
in presence or absence of gene expression as detected 
by conventional RT-PCR in CTCs and matched BMBxs, 
we lined up digitally the bands obtained for all the genes 
amplified in CTCs and BMBxs (same number of cycles) 
side by side (Additional file 1: Figure S1). We found that 
in 21 out of 28 comparisons, the presence or absence 
of detectable gene expression in CTCs and PCa cells 
microdissected from single bone metastasis of the same 
patients was concordant.
Discussion
Precise analysis of human tissue is necessary for evalu-
ation of gene expression. In this study, we wished to 
develop methods of gene expression analysis of CTCs and 
BMBxs in patients with mCRPC. We found that LCM, 
in conjunction with reliable methods of gene amplifica-
tion, is an option for the specific isolation and molecular 
analysis of small number of PCa cells present in BMBxs. 
In recent years, LCM systems with IR and UV lasers 
combined with efficient software have been developed to 
Fig. 3 Gene profiles shown by amplified aRNA obtained from CTCs and PCa tissue microdissected from FFPE BMBx. a RT‑PCR analysis of aRNA 
amplified from CTCs. b Representative section obtained from a FFPE BMBx of patient 24R‑G, with PCa metastatic to bone, as confirmed by pan‑CK 
immunostaining (top left picture). An adjacent section stained with H&E (top right) was used to microdissect (bottom left), and capture (bottom right) 
areas containing PCa cells only. Bar magnification, 200 μm. c RT‑PCR analysis of aRNA amplified from PCa microdissected from FFPE BMBx from four 
mCRPC patients
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isolate homogeneous cells precisely identified from het-
erogeneous tissues based on morphological criteria, and 
complemented by IHC phenotyping of the cell type of 
interest. In these LCM systems, the low-energy IR laser 
is fired to adhere spots within the selected tissue area to 
the PEN membrane of the glass slide, while the UV rap-
idly and precisely cuts out the zone defined to collect it 
in a collection cap [43]. In addition to RNA analysis, dif-
ferent types of molecular analyses can be performed on 
cells procured by LCM, including DNA and proteomic 
analyses [44, 45].
In this exploratory study with a small cohort of mCRPC 
patients, we demonstrated the feasibility of amplifying 
aRNA for gene analysis in limited numbers of PCa cells 
microdissected from FFPE BMBxs. We show that using a 
modified Eberwine’s procedure, adequate yields of RNA 
can be obtained for gene expression profiling. Our results 
obtained under tightly controlled conditions show good 
quality aRNA not only in freshly isolated CTCs, but also 
in aRNA amplified from FFPE BMBxs despite several stud-
ies having reported RNA degradation in formalin-fixed 
samples [46–48]. To avoid RNA degradation, we found 
that critical measures such as rapid processing of BMBxs 
after collection, preparation of all aqueous solutions using 
DEPC-treated water, and decontamination of all materi-
als and surfaces with ready-to-use surfactants that remove 
RNA and RNases from lab equipment, are mandatory 
throughout the procedure. Previous studies have reported 
LCM and DNA sequencing from a frozen bone metasta-
sis of a mCRPC patient [49], or gene expression analysis 
of total RNA directly obtained from snap-frozen bone 
marrow biopsies largely replaced by tumor [50] or frozen 
bone metastatic cores isolated at autopsy [12, 13, 51, 52]. 
However, in addition to our earliest analysis in a few PCa 
bone metastasis [53], the present study is the only report 
that, to the best of our knowledge, uses LCM and aRNA 
amplification for gene analysis of limited number of tumor 
cells microdissected from FFPE BMBx obtained from liv-
ing mCRPC patients. In spite of better RNA recovery and 
quality ascribed to frozen tissue [43, 44, 54], we found 
that its use as homogenate might be inadequate for gene 
expression analysis of PCa bone micrometastasis, due to 
dilution of PCa-specific genes by other genes expressed 
predominantly by bone cells. In that sense, the use of LCM 
to identify and capture precise cells from FFPE BMBxs 
seems to be more accurate to study gene expression after 
aRNA amplification. Limitations of this approach include 
the yield of bone biopsies (~50 %) and the need for suffi-
cient tissue (~9000 µm2) for LCM.
Besides the clinical utility of the CTC count to moni-
tor treatment response and predict survival in mCRPC 
patients [11], enriched CTCs can also be used for 
molecular studies that may provide important clues to 
understand the biology behind metastatic dissemination 
of PCa. Analysis of CTCs may also lead to the discovery 
of novel predictive and prognostic biomarkers or demon-
strate targets for therapy. Many groups have succeeded in 
genomic and transcriptomic profiling of CTCs in patients 
with PCa [29, 55–62]; however, to our knowledge, none 
of them have compared molecular features of CTCs 
with those of bone micrometastasis in mCRPC patients. 
Because significantly higher CTC numbers are detected 
in mCRPC patients with bone metastasis relative to those 
without bone metastatic lesions [38], CTCs in patients 
are likely to derive from bone metastatic deposits. Thus, 
we hypothesized that gene signatures of skeletal metas-
tasis may be mirrored in CTCs in each mCRPC patient. 
Our study suggests some concordance in presence or 
absence of gene expression in CTCs and single bone 
lesions of the same mCRPC patients. An obvious limita-
tion of our study is the small sample size and the biopsy-
targeting of single bone lesions; future studies with more 
patients and perhaps more biopsy sites in individual 
patients may provide additional clarification.
Data collected from autopsy studies in men who died of 
mCRPC have revealed substantial heterogeneity among 
tumor cells in bone metastases within the same patient 
[63–65]. Therefore, we surmise that presence or absence 
of detectable gene expression in CTCs, rather than gene 
expression levels, may provide a more clinically relevant 
overview of the genomic landscape in each mCRPC 
patient. Detectable gene expression in CTCs may suggest 
a druggable target; however, this result may ultimately be 
unreliable due to heterogeneity of target gene expression 
among separate metastatic deposits within individual 
patients. Similarly, absence of target gene expression in 
CTCs may not rule out target gene expression in some 
metastatic deposits. Therefore, this exploratory analy-
sis raises concerns about relying on CTCs to predict 
response to therapy.
In this study we used CellSearch®, an EpCAM-based 
platform utilized for capturing of epithelial tumor cells 
from peripheral blood of mCRPC patients. Like other 
CTC-enriching technologies that rely on the expression 
of epithelial markers, the CellSearch® system does not 
have the capacity to isolate CTCs that might have gone 
through EMT. However, we found that the genes that 
code for the epithelial marker EpCAM and the mesen-
chymal marker vimentin were co-expressed in many of 
our patients’ CTC samples, suggesting a partial EMT. 
These results are in agreement with the findings of other 
groups that reported expression of EMT markers in 
EpCAM-positive CTCs [66–68]. We also found Vimentin 
to be expressed by most of the pure PCa tissues micro-
dissected from BMBx. Our results are supported by IHC 
studies by Sethi et al. that show vimentin overexpression 
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at the invasive front of bone metastases of PCa patients 
and E-cadherin within the center of the lesion [69], and 
those of Bryden et  al. who reported lower E-cadherin 
expression in poorly differentiated bone metastases than 
in more differentiated ones [70]. The expression of mes-
enchymal markers in PCa metastatic to bone could be 
ascribed to osseous factors that offer a selective growth 
advantage for tumor cells with a mesenchymal pheno-
type, as opposed to other tissues (e.g., lung) that promote 
mesenchymal-to-epithelial transition in colonizing can-
cer cells [71, 72].
Conclusions
To our knowledge, this exploratory study is the first to 
demonstrate the feasibility of simultaneous gene analy-
sis in small numbers of CTCs and laser-captured, micro-
dissected bone metastases in living mCRPC patients. 
Our data suggest that partial EMT might take place in 
bone metastatic PCa cells and in CTCs captured using 
EpCAM-based enrichment platforms. In this study, we 
found some concordance in gene expression profile of 
CTCs and PCa cells microdissected from single bone 
lesions of the same patients. This exploratory analy-
sis raises concerns about relying on CTCs to predict 
response to therapy. Further investigations using a larger 
cohort of patients and new technologies capable to enrich 
the full spectrum of CTCs are needed to define more pre-
cisely the genomic landscaping of mCRPC through the 
use of these “liquid biopsies”.
Authors’ contributions
RDB and H‑RCK conceived and designed the experiments. WJC, DSMO, AJN, 
and LEM performed the experiments. HAD performed image‑guided bone 
marrow core biopsies. RDB, H‑RCK, MLC, and EH analyzed the data. EH and 
MLC contributed patients’ biospecimens. RDB wrote the paper. All authors 
read and approved the final manuscript.
Author details
1 Department of Urology, Wayne State University School of Medicine and Kar‑
manos Cancer Institute, 540 E. Canfield, Scott Hall # 9105, Detroit, MI 4820, 
USA. 2 Department of Pathology, Wayne State University School of Medicine 
and Karmanos Cancer Institute, Detroit, MI, USA. 3 Department of Radiology, 
Wayne State University School of Medicine and Karmanos Cancer Institute, 
Detroit, MI, USA. 4 Department of Oncology, Wayne State University School 
of Medicine and Karmanos Cancer Institute, Detroit, MI, USA. 
Acknowledgements
This work was supported by a Grant from The Sage Foundation (RDB and 
MLC, support for KCI Bone Metastasis Biobank), Department of Defense grant 
W81XWH‑11‑1‑0050 (subcontract to HRCK, RDB and MLC), and Wayne State 
School of Medicine (start‑up funds to RDB). The authors would like to thank 
the patients who consented to provide blood and bone biopsies that were 
used in this study.
Additional file
Additional file 1: Figure S1. Side by side comparison of gene expres‑
sion (detectable/non‑detectable) shown by aRNA from CTCs and BMBx 
after reverse transcription and PCR with same number of cycles.
Competing interests
The authors declare that they have no competing interests.
Received: 25 November 2015   Accepted: 5 March 2016
References
 1. Inoue T, Segawa T, Kamba T, Yoshimura K, Nakamura E, Nishiyama H, 
et al. Prevalence of skeletal complications and their impact on survival 
of hormone refractory prostate cancer patients in Japan. Urology. 
2009;73(5):1104–9. doi:10.1016/j.urology.2008.07.062.
 2. Berruti A, Tucci M, Mosca A, Tarabuzzi R, Gorzegno G, Terrone C, et al. 
Predictive factors for skeletal complications in hormone‑refractory 
prostate cancer patients with metastatic bone disease. Br J Cancer. 
2005;93(6):633–8. doi:10.1038/sj.bjc.6602767.
 3. Dunn TA, Fedor HL, De Marzo AM, Luo J. Molecular profiling of indolent 
human prostate cancer: tackling technical challenges to achieve 
high‑fidelity genome‑wide data. Asian J Androl. 2012;14(3):385–92. 
doi:10.1038/aja.2011.147.
 4. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. 
Integrative genomic profiling of human prostate cancer. Cancer Cell. 
2010;18(1):11–22. doi:10.1016/j.ccr.2010.05.026.
 5. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al. 
Integrative molecular concept modeling of prostate cancer progression. 
Nat Genet. 2007;39(1):41–51. doi:10.1038/ng1935.
 6. Ciray I, Astrom G, Sundstrom C, Hagberg H, Ahlstrom H. Assess‑
ment of suspected bone metastases. CT with and without clinical 
information compared to CT‑guided bone biopsy. Acta Radiol. 
1997;38(5):890–5.
 7. Alix‑Panabieres C, Pantel K. Challenges in circulating tumour cell research. 
Nat Rev Cancer. 2014;14(9):623–31. doi:10.1038/nrc3820.
 8. Zhe X, Cher ML, Bonfil RD. Circulating tumor cells: finding the needle in 
the haystack. Am J Cancer Res. 2011;1(6):740–51.
 9. Miyamoto DT, Sequist LV, Lee RJ. Circulating tumour cells‑moni‑
toring treatment response in prostate cancer. Nat Rev Clin Oncol. 
2014;11(7):401–12. doi:10.1038/nrclinonc.2014.82.
 10. Alix‑Panabieres C, Pantel K. Circulating tumor cells: liquid 
biopsy of cancer. Clin Chem. 2013;59(1):110–8. doi:10.1373/
clinchem.2012.194258.
 11. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, 
et al. Circulating tumor cells predict survival benefit from treatment 
in metastatic castration‑resistant prostate cancer. Clin Cancer Res. 
2008;14(19):6302–9. doi:10.1158/1078‑0432.CCR‑08‑0872.
 12. Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, et al. 
Differential expression of angiogenesis associated genes in prostate 
cancer bone, liver and lymph node metastases. Clin Exp Metastasis. 
2008;25(4):377–88. doi:10.1007/s10585‑007‑9116‑4.
 13. Mehra R, Kumar‑Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE, et al. 
Characterization of bone metastases from rapid autopsies of prostate 
cancer patients. Clin Cancer Res. 2011;17(12):3924–32. doi:10.1158/1078‑
0432.CCR‑10‑3120.
 14. Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior 
SW, et al. C‑kit and its ligand stem cell factor: potential contribution to 
prostate cancer bone metastasis. Neoplasia. 2008;10(9):996–1003.
 15. Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M, et al. 
Matrix metalloproteinase activity and osteoclasts in experimental pros‑
tate cancer bone metastasis tissue. Am J Pathol. 2005;166(4):1173–86. 
doi:10.1016/S0002‑9440(10)62337‑1.
 16. Carter LE, Kilroy G, Gimble JM, Floyd ZE. An improved method 
for isolation of RNA from bone. BMC Biotechnol. 2012;12:5. 
doi:10.1186/1472‑6750‑12‑5.
 17. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eber‑
wine JH. Amplified RNA synthesized from limited quantities of heteroge‑
neous cDNA. Proc Natl Acad Sci USA. 1990;87(5):1663–7.
 18. Okello JB, Rodriguez L, Poinar D, Bos K, Okwi AL, Bimenya GS, et al. 
Quantitative assessment of the sensitivity of various commercial reverse 
transcriptases based on armored HIV RNA. PLoS One. 2010;5(11):e13931. 
doi:10.1371/journal.pone.0013931.
Page 11 of 12Cho et al. J Transl Med  (2016) 14:72 
 19. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real‑time 
RT‑PCR. Nat Protoc. 2006;1(3):1559–82. doi:10.1038/nprot.2006.236.
 20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using 
real‑time quantitative PCR and the 2(‑Delta Delta C(T)) Method. Methods. 
2001;25(4):402–8. doi:10.1006/meth.2001.1262.
 21. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO. Ep‑CAM: a 
human epithelial antigen is a homophilic cell‑cell adhesion molecule. J 
Cell Biol. 1994;125(2):437–46.
 22. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al. Fre‑
quent EpCam protein expression in human carcinomas. Hum Pathol. 
2004;35(1):122–8.
 23. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. 
Prostate specific antigen best practice statement: 2009 update. J Urol. 
2009;182(5):2232–41. doi:10.1016/j.juro.2009.07.093.
 24. Masuda H, Fukabori Y, Nakano K, Takezawa Y, CSuzuki T, Yamanaka H. 
Increased expression of bone morphogenetic protein‑7 in bone meta‑
static prostate cancer. Prostate. 2003;54(4):268–74. doi:10.1002/pros.10193.
 25. Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E. Bone morphogenetic 
protein 7 is expressed in prostate cancer metastases and its effects on 
prostate tumor cells depend on cell phenotype and the tumor microen‑
vironment. Neoplasia. 2010;12(2):192–205.
 26. Bonfil RD, Dong Z, Trindade Filho JC, Sabbota A, Osenkowski P, Nabha S, 
et al. Prostate cancer‑associated membrane type 1‑matrix metallopro‑
teinase: a pivotal role in bone response and intraosseous tumor growth. 
Am J Pathol. 2007;170(6):2100–11. doi:10.2353/ajpath.2007.060720.
 27. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun 
XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor 
genes in prostate cancer. Science. 2005;310(5748):644–8. doi:10.1126/
science.1117679.
 28. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, et al. 
Characterization of TMPRSS2:eTV5 and SLC45A3:ETV5 gene fusions in 
prostate cancer. Cancer Res. 2008;68(1):73–80. doi:10.1158/0008‑5472.
CAN‑07‑5352.
 29. Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, et al. 
TMPRSS2‑ERG status in circulating tumor cells as a predictive biomarker 
of sensitivity in castration‑resistant prostate cancer patients treated 
with abiraterone acetate. Eur Urol. 2011;60(5):897–904. doi:10.1016/j.
eururo.2011.07.011.
 30. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, et al. 
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful 
waiting cohort. Oncogene. 2007;26(31):4596–9. doi:10.1038/sj.onc.1210237.
 31. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, et al. 
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal 
human prostate cancer. Oncogene. 2008;27(3):253–63. doi:10.1038/
sj.onc.1210640.
 32. John J, Powell K, Conley‑Lacomb MK, Chinni SR. TMPRSS2‑ERG fusion 
gene expression in prostate tumor cells and its clinical and biological sig‑
nificance in prostate cancer progression. J Cancer Sci Ther. 2008;4(4):94–
101. doi:10.4172/1948‑5956.1000119.
 33. Wegiel B, Bjartell A, Culig Z, Persson JL. Interleukin‑6 activates PI3 K/Akt 
pathway and regulates cyclin A1 to promote prostate cancer cell survival. 
Int J Cancer. 2008;122(7):1521–9. doi:10.1002/ijc.23261.
 34. Ara T, Declerck YA. Interleukin‑6 in bone metastasis and cancer progres‑
sion. Eur J Cancer. 2010;46(7):1223–31. doi:10.1016/j.ejca.2010.02.026.
 35. Domingo‑Domenech J, Oliva C, Rovira A, Codony‑Servat J, Bosch M, 
Filella X, et al. Interleukin 6, a nuclear factor‑kappaB target, predicts resist‑
ance to docetaxel in hormone‑independent prostate cancer and nuclear 
factor‑kappaB inhibition by PS‑1145 enhances docetaxel antitumor 
activity. Clin Cancer Res. 2006;12(18):5578–86. doi:10.1158/1078‑0432.
CCR‑05‑2767.
 36. Morrissey C, Lai JS, Brown LG, Wang YC, Roudier MP, Coleman IM, et al. 
The expression of osteoclastogenesis‑associated factors and osteoblast 
response to osteolytic prostate cancer cells. Prostate. 2010;70(4):412–24. 
doi:10.1002/pros.21075.
 37. Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell 
shape, motility, and adhesion during the epithelial to mesenchymal 
transition. FASEB J. 2010;24(6):1838–51. doi:10.1096/fj.09‑151639.
 38. Thalgott M, Rack B, Maurer T, Souvatzoglou M, Eiber M, Kress V, et al. 
Detection of circulating tumor cells in different stages of prostate 
cancer. J Cancer Res Clin Oncol. 2013;139(5):755–63. doi:10.1007/
s00432‑013‑1377‑5.
 39. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al. 
Circulating tumour cells as prognostic markers in progressive, castration‑
resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 
2009;10(3):233–9. doi:10.1016/S1470‑2045(08)70340‑1.
 40. Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, et al. Circulat‑
ing tumour cell (CTC) counts as intermediate end points in castration‑
resistant prostate cancer (CRPC): a single‑centre experience. Ann Oncol. 
2009;20(1):27–33. doi:10.1093/annonc/mdn544.
 41. Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, et al. 
Predictors of prostate cancer tissue acquisition by an undirected core 
bone marrow biopsy in metastatic castration‑resistant prostate cancer–a 
Cancer and Leukemia Group B study. Clin Cancer Res. 2005;11(22):8109–
13. doi:10.1158/1078‑0432.CCR‑05‑1250.
 42. Spritzer CE, Afonso PD, Vinson EN, Turnbull JD, Morris KK, Foye A, et al. 
Bone marrow biopsy: RNA isolation with expression profiling in men with 
metastatic castration‑resistant prostate cancer–factors affecting diagnos‑
tic success. Radiology. 2013;269(3):816–23. doi:10.1148/radiol.13121782.
 43. Bidarimath M, Edwards AK, Tayade C. Laser capture microdissection 
for gene expression analysis. Methods Mol Biol. 2015;1219:115–37. 
doi:10.1007/978‑1‑4939‑1661‑0_10.
 44. Mukherjee S, Rodriguez‑Canales J, Hanson J, Emmert‑Buck MR, Tangrea 
MA, Prieto DA, et al. Proteomic analysis of frozen tissue samples using 
laser capture microdissection. Methods Mol Biol. 2013;1002:71–83. 
doi:10.1007/978‑1‑62703‑360‑2_6.
 45. Domazet B, Maclennan GT, Lopez‑Beltran A, Montironi R, Cheng L. Laser 
capture microdissection in the genomic and proteomic era: targeting the 
genetic basis of cancer. Int J Clin Exp Pathol. 2008;1(6):475–88.
 46. Chung JY, Braunschweig T, Hewitt SM. Optimization of recovery of 
RNA from formalin‑fixed, paraffin‑embedded tissue. Diagn Mol Pathol. 
2006;15(4):229–36. doi:10.1097/01.pdm.0000213468.91139.2d.
 47. von Ahlfen S, Missel A, Bendrat K, Schlumpberger M. Determinants of 
RNA quality from FFPE samples. PLoS One. 2007;2(12):e1261. doi:10.1371/
journal.pone.0001261.
 48. Arzt L, Kothmaier H, Quehenberger F, Halbwedl I, Wagner K, Maier‑
hofer T, et al. Evaluation of formalin‑free tissue fixation for RNA and 
microRNA studies. Exp Mol Pathol. 2011;91(2):490–5. doi:10.1016/j.
yexmp.2011.05.007.
 49. Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, et al. Suc‑
cessful whole‑exome sequencing from a prostate cancer bone metas‑
tasis biopsy. Prostate Cancer Prostatic Dis. 2014;17(1):23–7. doi:10.1038/
pcan.2013.37.
 50. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, 
et al. Increased expression of genes converting adrenal androgens to 
testosterone in androgen‑independent prostate cancer. Cancer Res. 
2006;66(5):2815–25. doi:10.1158/0008‑5472.CAN‑05‑4000.
 51. Larson SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, et al. 
Characterization of osteoblastic and osteolytic proteins in prostate cancer 
bone metastases. Prostate. 2013;73(9):932–40. doi:10.1002/pros.22639.
 52. Zhang X, Coleman I, Brown LG, True LD, Kollath L, Lucas JM, et al. SRRM4 
expression and the loss of REST activity may promote the emergence of 
the neuroendocrine phenotype in castration‑resistant prostate cancer. 
Clin Cancer Res. 2015. doi:10.1158/1078‑0432.CCR‑15‑0157.
 53. Mainetti LE, Zhe X, Diedrich J, Saliganan AD, Cho WJ, Cher ML, et al. 
Bone‑induced c‑kit expression in prostate cancer: a driver of intraosseous 
tumor growth. Int J Cancer. 2015;136(1):11–20. doi:10.1002/ijc.28948.
 54. Li J, Gregory SG, Garcia‑Blanco MA, Armstrong AJ. Using circulating 
tumor cells to inform on prostate cancer biology and clinical utility. Crit 
Rev Clin Lab Sci. 2015;52(4):191–210. doi:10.3109/10408363.2015.102343
0.
 55. Giesing M, Driesel G, Molitor D, Suchy B. Molecular phenotyping 
of circulating tumour cells in patients with prostate cancer: pre‑
diction of distant metastases. BJU Int. 2012;110(11 Pt C):1202–11. 
doi:10.1111/j.1464‑410X.2012.11534.x.
 56. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A’Hern R, et al. 
Characterization of ERG, AR and PTEN gene status in circulating tumor 
cells from patients with castration‑resistant prostate cancer. Cancer Res. 
2009;69(7):2912–8. doi:10.1158/0008‑5472.CAN‑08‑3667.
 57. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, et al. 
Androgen receptor signaling in circulating tumor cells as a marker of hor‑
monally responsive prostate cancer. Cancer Discov. 2012;2(11):995–1003. 
doi:10.1158/2159‑8290.CD‑12‑0222.
Page 12 of 12Cho et al. J Transl Med  (2016) 14:72 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 58. Cann GM, Gulzar ZG, Cooper S, Li R, Luo S, Tat M, et al. mRNA‑Seq of 
single prostate cancer circulating tumor cells reveals recapitulation of 
gene expression and pathways found in prostate cancer. PLoS One. 
2012;7(11):e49144. doi:10.1371/journal.pone.0049144.
 59. Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME. Detection of andro‑
gen receptor mutations in circulating tumor cells in castration‑
resistant prostate cancer. Clin Chem. 2010;56(9):1492–5. doi:10.1373/
clinchem.2010.143297.
 60. Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez‑Espinoza R, 
et al. Fluorescence in situ hybridization analysis of circulating tumor 
cells in metastatic prostate cancer. Clin Cancer Res. 2009;15(6):2091–7. 
doi:10.1158/1078‑0432.CCR‑08‑2036.
 61. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, et al. 
Isolation and genomic analysis of circulating tumor cells from castra‑
tion resistant metastatic prostate cancer. BMC Cancer. 2012;12:78. 
doi:10.1186/1471‑2407‑12‑78.
 62. Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, 
Cruz‑Gordillo P, et al. Whole‑exome sequencing of circulating tumor 
cells provides a window into metastatic prostate cancer. Nat Biotechnol. 
2014;32(5):479–84. doi:10.1038/nbt.2892.
 63. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, et al. Andro‑
gen‑independent prostate cancer is a heterogeneous group of diseases: 
lessons from a rapid autopsy program. Cancer Res. 2004;64(24):9209–16. 
doi:10.1158/0008‑5472.CAN‑04‑2442.
 64. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, et al. 
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple 
metastatic prostate cancer tissues. Cancer Res. 1998;58(2):204–9.
 65. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, et al. Pheno‑
typic heterogeneity of end‑stage prostate carcinoma metastatic to bone. 
Hum Pathol. 2003;34(7):646–53.
 66. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, 
et al. Circulating tumor cells from patients with advanced prostate and 
breast cancer display both epithelial and mesenchymal markers. Mol 
Cancer Res. 2011;9(8):997–1007. doi:10.1158/1541‑7786.MCR‑10‑0490.
 67. Chen CL, Mahalingam D, Osmulski P, Jadhav RR, Wang CM, Leach RJ, 
et al. Single‑cell analysis of circulating tumor cells identifies cumulative 
expression patterns of EMT‑related genes in metastatic prostate cancer. 
Prostate. 2013;73(8):813–26. doi:10.1002/pros.22625.
 68. Pal SK, He M, Wilson T, Liu X, Zhang K, Carmichael C, et al. Detection and 
phenotyping of circulating tumor cells in high‑risk localized prostate 
cancer. Clinical Genitourin Cancer. 2015;13(2):130–6. doi:10.1016/j.
clgc.2014.08.014.
 69. Sethi S, Macoska J, Chen W, Sarkar FH. Molecular signature of epithelial‑
mesenchymal transition (EMT) in human prostate cancer bone metasta‑
sis. Am J Transl Res. 2010;3(1):90–9.
 70. Bryden AA, Freemont AJ, Clarke NW, George NJ. Paradoxical expression of 
E‑cadherin in prostatic bone metastases. BJU Int. 1999;84(9):1032–4.
 71. Turley EA, Veiseh M, Radisky DC, Bissell MJ. Mechanisms of disease: 
epithelial‑mesenchymal transition–does cellular plasticity fuel neoplastic 
progression? Nat Clin Pract Oncol. 2008;5(5):280–90. doi:10.1038/
ncponc1089.
 72. Kyprianou N. ASK‑ing EMT not to spread cancer. Proc Natl Acad Sci USA. 
2010;107(7):2731–2. doi:10.1073/pnas.0914721107.
